Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $18

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

July 1, 2022

1 minute read

Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.

Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket

November 14, 8:41 AM

INVO Bioscience, Inc. (NASDAQ: INVO) shares surged in pre-market trading after the company posted a narrower loss for the third quarter.

January 27, 8:43 AM

JMP Securities analyst Patrick Walravens maintains Confluent (NASDAQ:CFLT) with a Market Outperform and lowers the price target from $45 to $33.

October 3, 3:37 PM

Analysts have provided the following ratings for Rackspace Tech (NASDAQ:RXT) within the last quarter:

August 25, 8:01 AM

Over the past 3 months, 10 analysts have published their opinion on Advanced Drainage Systems (NYSE:WMS) stock. These…